Sachin D. Patel acquisition disclosure under SEBI Takeover Exemption
The disclosure was submitted by Sachin D. Patel to NSE under the SEBI takeover code. The filing references Regulation 10(6) of the SEBI (SAST) Regulations, 2011, which provides exemptions from the requirement to make a public offer to shareholders in certain specified circumstances. The exact value, number of shares acquired, and prior and post-acquisition holding percentages are not disclosed in the excerpt provided. This is a formal regulatory filing category required whenever a party acquires shares in reliance on a specific SEBI exemption.
Why it mattersRegulation 10(6) exemptions typically cover acquisitions by promoters, existing shareholders or other specified categories where the acquirer is exempt from the general requirement to make an open offer; this filing flags a structured acquisition rather than a market-triggered mandatory bid situation.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Gujarat Themis Biosyn Disclosure · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026